| Bioactivity | Avizakimab (BOS161721) is a humanized IgG1 monoclonal antibody that targets interleukin-21[1]. |
| Invitro | Avizakimab (BOS161721) 可阻止 IL-21 与 IL-21 受体 (IL-21R) 结合，并抑制生物活性[1]。Avizakimab 可抑制 IL-21 诱导的下游信号传导、浆细胞分化和自然杀伤细胞激活，并抑制抗体对匙孔戚血蓝蛋白 (keyhole limpet hemocyanin; KLH) 抗原的反应[1]。 |
| Name | Avizakimab |
| CAS | 2229685-51-0 |
| Appearance | Liquid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Hussaini A, et al. A Double-Blind, Phase I, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BOS161721 in Healthy Subjects. Clin Transl Sci. 2020 Mar;13(2):337-344. |